Company Profile

Nereus Pharmaceuticals Inc
Profile last edited on: 9/14/19      CAGE:       UEI:

Business Identifier: Therapeutics for treatment of inflammation and infectious diseases
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

10480 Wateridge Circle
San Diego, CA 92121
   (858) 587-4090
Location: Single
Congr. District: 52
County: San Diego

Public Profile

In 2012, Nereus was acquired by Triphase Research and Development. Previously Nereus had been focused on the commercialization of natural small-molecule compounds for the treatment of inflammatory diseases, cancer, and infectious diseases. The Company had access to novel chemical libraries as well as a proprietary marine cell culture technology. The firm is developing an integrated platform technologies used to identify novel biologically active compounds. Nereus Pharmaceuticals has created a pipeline of two pre-clinical candidates and an additional three new chemical entity (NCE) leads currently in development. Nereus intends to file an IND for both preclinical products in 2005. These targeted anticancer compounds are 1) a novel selective tumor vascular disrupting agent (VDA) for the treatment of certain solid tumors such as colon carcinoma, non small cell lung, thyroid and breast cancer and 2) a second generation proteasome inhibitor (the same class of therapeutic as Millennium's Velcade) for the treatment of multiple myeloma and/or solid tumors. Nereus also believes that its development pipeline should enable the Company to take an additional one to two compounds into human clinical trials in 2006/2007. All of Nereus' early compounds are in high value therapeutic classes such as targeted cancer treatments, which, if approved, would have substantial market potential. Over twenty-five additional development leads comprise the Company's current portfolio. I

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 2 NIH $840,246
Project Title: TTL - A New Class Of Oral TNF-Alpha Synthesis Inhibitors

Key People / Management

  Kobi M Sethna -- President and Founder

  A Andrew Dorr -- Chief Scientific Officer

  William H Fenical -- Founder

  Stan Fleming -- Founder

  G Kenneth Lloyd -- VP, R&D & Chief Scientific Officer

  Sanford J Madigan -- VP, Corporate Development

  Michael A Palladino -- Founder

  Michael A Palladino -- Chief Technical Officer & Scientific Cofounder

  Donald J Salz -- VP, Finance & Administration

Company News